Abstracts tagged "axial spondyloarthritis"

Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Jürgen Braun¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Desiree van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
Abstract Number: 2324 • 2014 ACR/ARHP Annual Meeting
Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It
Hélène Che^1,2, Adrien Etcheto^2,3, Emmanuelle Dernis Labous^4,5, Henri Nataf⁵, Patrick Boumier⁵, Philippe Breuillard⁵, Marianne Durandin-Truffinet⁵, Jacques Fechtenbaum^2,5, Veronique Gaud-Listrat^2,5, Bernard Giraud⁵, Christophe Hudry^2,5, Sylvain La Batide Alanore⁵, Patricia Le Devic⁵, Patrick Le Goux⁵, Agnes Lebrun^2,5, Emmanuel Maheu⁵, Bertrand Moura⁵, Minh Nguyen^2,5, Antoinette Sacchi⁵, Xavier Ayral^5,6, Anne Blanchais^2,5, Severine Neveu^2,5, Maxime Dougados^2,5,7 and Anna Molto^2,5,7, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Rhumatologie, Ch Du Mans, Le Mans, France, ⁵Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ⁶Université Paris René Descartes and Hôpital Cochin, paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France
Background/Purpose The current recommendations for optimal monitoring of axial spondyloarthritis (SpA) are to assess regularly disease activity. The two proposed tools comprise clinical aspects as…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2302 • 2014 ACR/ARHP Annual Meeting
Classification of Juvenile Spondyloarthropathies According to ASAS Criteria
Marìa M. Katsicas¹ and Ricardo A. G. Russo², ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose The juvenile spondyloarthropathies (JSpA) are a group of related seronegative rheumatic diseases characterized by involvement of the axial , peripheral large joints and entheses.…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 1895 • 2014 ACR/ARHP Annual Meeting
Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
Pamela Weiss¹, Rui Xiao^2,3 and Nancy Chauvin⁴, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The prevalence of sacroiliitis in children with juvenile spondyloarthritis (JSpA) at diagnosis is unknown. We aimed to evaluate: 1) the prevalence of sacroiliitis at…
Abstract Number: 1893 • 2014 ACR/ARHP Annual Meeting
Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment…
Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting
Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
Brigitte Michelsen¹, Andreas P. Diamantopoulos², Arthur Kavanaugh³ and Glenn Haugeberg^1,4, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway
Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…
Abstract Number: 855 • 2014 ACR/ARHP Annual Meeting
Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies evaluating predictors of major clinical response in patients with non-radiographic axial SpA (nr-axSpA) receiving treatment with anti-TNF agents have been limited by…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 2938 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
J Sieper¹, D van der Heijde², M Dougados³, Walter P. Maksymowych⁴, J Boice⁵, G Bergman⁵, S Curtis⁵, A Tzontcheva⁵, S Huyck⁵ and HH Weng⁵, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Paris-Descartes University, Paris, France, ⁴Department of Medicine, University of Alberta, Alberta, AK, ⁵Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose Axial spondyloarthritis (axSpA), including ankylosing spondylitis and nonradiographic axial SpA (nr-axSpA), is a chronic inflammatory disease marked by back pain and progressive spinal stiffness.…
Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Lennart TH Jacobsson¹, Tomas Husmark², Elke Theander³, Kenneth Henriksson⁴, Katharina Büsch⁵ and Martin Johansson⁵, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Rheumatology city clinic, Stockholm, Sweden, Stockholm, Sweden, ⁵AbbVie AB, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…
Abstract Number: 2604 • 2014 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort
Azucena Hernández-Sanz¹, Victoria Navarro-Compán², Cristina Fernández-Carballido³, Carlos Montilla-Morales⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹H. Virgen de la Salud, Toledo, Spain, ²Rheumatology, University Hospital La Paz, Madrid, Spain, ³Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ⁴H. de Salamanca, Salamanca, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose New ASAS criteria for axial spondyloarthritis (axSpA) have two entrances: the imaging and clinical arm (presence of HLA B27). The imaging arm allows classifying patients…
Abstract Number: 585 • 2014 ACR/ARHP Annual Meeting
Optimism Levels Are Moderate and Similar in Patients with Axial Spondyloarthritis and Chronic Low Back Pain, and Are Related to Mental Quality of Life but Not Physical Quality of Life. a Cross Sectional Study of 277 Patients
Sarah Kreis^1,2,3, Anna Molto^2,3, Florian Bailly^2,3, Sabrina Dadoun^2,3, Stephanie Fabre^2,3,4, Christophe Hudry², Franck Zenasni⁵, Sylvie Rozenberg^2,3, Edouard Perthuiset⁴, Bruno Fautrel^2,6 and Laure Gossec^2,7, ¹Institut de Psychologie, Laboratoire de Psychopathologie et Processus de Santé EA4057, Université Paris Descartes, Boulogne-Billancourt, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Pitié-Salpêtrière Hospital, AP-HP, Rheumatology department, paris, France, ⁴Pontoise University Hospital, pontoise, France, ⁵Institut de Psychologie, Laboratoire de Psychopathologie et Processus de Santé EA4057, Université Paris Descartes, Paris, France, Boulogne-Billancourt, France, ⁶Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁷Rheumatology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
Background/Purpose Axial Spondyloarthritis (AxSpA) and chronic low back pain (LBP) are very different chronic rheumatic diseases in terms of physiopathology and prognosis but both have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].